A549-HLA-A2.01 NTCC®人类白细胞抗原表面表达肺癌细胞株 BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

A549-HLA-A2.01 NTCC®人类白细胞抗原表面表达肺癌细胞株

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

A549-HLA-A2.01 is a cell line derived from the human lung carcinoma cell line A549. It has been genetically modified to express the HLA-A2.01 molecule on its surface. HLA-A2.01 is a human leukocyte antigen (HLA) class I molecule that is present in approximately 50% of the human population.

Key Features

• A549 Origin: Derived from the A549 lung carcinoma cell line, which retains many characteristics of type II alveolar epithelial cells.

• HLA-A2.01 Expression: Stably expresses the HLA-A2.01 molecule on its surface.

• Research Applications

  • Immunology Research: Used to study T cell responses to viral and tumor antigens presented by HLA-A2.01.

  • Vaccine Development: Used to evaluate the efficacy of vaccines targeting antigens presented by HLA-A2.01.

  • Cancer Research: Used to model tumor-immune interactions and to develop immunotherapies for cancer.

Significance of HLA-A2.01

HLA molecules play a crucial role in the immune system by presenting antigens to T cells. T cells can then recognize and eliminate cells that are infected with viruses or have become cancerous. HLA-A2.01 is one of the most common HLA molecules in the human population, making it an important target for immunotherapy research.

Note:

• The use of A549-HLA-A2.01 cells requires appropriate safety measures in the laboratory, as it involves working with genetically modified cells.

• The expression and function of HLA-A2.01 can be influenced by various factors, such as cell culture conditions and the presence of other cellular proteins.

Image

生产厂家Supplier:

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail:BioVector@163.com

http://www.biovector.net